“I think it was stat sig, but not enough to halt it prematurely, out of reasons of stat power, but close enough to ask for another unplanned interim analysis at 75%.”

Fair assessment. Either way, the data is not ready to be submitted to any regulatory agency, FDA, UK, Phillippines, etc. IMO, it doesn’t seem wise to unblind and shop the data around.